And anti‐PD‐1/PD‐L1 immunotherapy might be used as a potential candidate for GC patients with positive PD‐L1 expression, MMR deficiency, and negative HER2 status. This evidence concerns the gene ERBB2 and hyperinsulinemic hypoglycemia, familial, 4.